San Francisco Bay Area biotech stories.
Monday, August 6, 2012
Exelixis shares fall on stock, debt offering news
plans to offer 20 million shares and $225 million in debt, the South San Francisco biotech company said Monday.
The company (NASDAQ: EXEL),
which could win approval in late November for its cancer drug cabozantinib
, saw its stock fall 13 percent after the news. On the day, Exelixis stock lost 73 cents, closing at $4.85 per share.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)